Using the second approach, we observed numerically worse clinical outcomes for all three other KRAS/TP53 configurations compared with the reference category of KRASmut/TP53mut tumours for both PFS and OS and in both univariate and multivariate analyses (Suppl. 6 and 7). This evidence concerns the gene TP53 and neoplasm.